B. Riley Research Analysts Cut Earnings Estimates for CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at B. Riley cut their FY2026 EPS estimates for shares of Capricor Therapeutics in a research note issued to investors on Tuesday, November 11th. B. Riley analyst M. El-Saadi now forecasts that the biotechnology company will earn $1.11 per share for the year, down from their prior estimate of $1.27. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

A number of other research analysts have also issued reports on CAPR. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 target price on shares of Capricor Therapeutics in a report on Thursday, September 25th. Finally, Roth Capital lifted their price target on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $22.38.

Capricor Therapeutics Price Performance

CAPR traded up $0.11 during trading hours on Thursday, hitting $5.98. 595,767 shares of the stock were exchanged, compared to its average volume of 1,835,416. The stock has a market cap of $273.52 million, a price-to-earnings ratio of -3.66 and a beta of 0.58. Capricor Therapeutics has a 12 month low of $5.43 and a 12 month high of $20.75. The stock has a 50-day simple moving average of $6.55 and a 200-day simple moving average of $8.26.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54).

Institutional Trading of Capricor Therapeutics

Large investors have recently modified their holdings of the company. Octagon Capital Advisors LP bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $4,270,000. GSA Capital Partners LLP bought a new stake in Capricor Therapeutics in the third quarter valued at about $1,555,000. Jump Financial LLC acquired a new stake in Capricor Therapeutics during the first quarter valued at approximately $1,547,000. Goldman Sachs Group Inc. boosted its stake in Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after buying an additional 116,373 shares in the last quarter. Finally, Woodline Partners LP grew its position in Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after acquiring an additional 99,384 shares during the period. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.